论文部分内容阅读
磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶体蛋白(PI3K/Akt/mTOR)信号转导通路通过PTEN基因功能的失常或者被其他信号激活后,抑制细胞凋亡,促进细胞周期运行,致细胞增殖,促进血管形成和恶性肿瘤的侵袭和转移,在卵巢癌的发生和发展中发挥重要作用,且与卵巢癌化疗耐药密切相关。因此该通路中的受体及激酶可能成为卵巢癌抗癌药物的潜在靶点,随着对该通路研究的逐渐深入以及抑制剂的发现和发明,针对该信号转导通路开发新的肿瘤治疗药物,靶向基因治疗,以及寻找降低化疗耐药的方法,无疑对卵巢癌治疗具有重要意义。
Phosphatidylinositol 3 kinase / protein kinase B / mammalian target of rapamycin (PI3K / Akt / mTOR) signal transduction pathway by PTEN gene dysfunction or activation by other signals, inhibition of apoptosis and promote Cell cycle, cell proliferation, promoting angiogenesis and malignant tumor invasion and metastasis, plays an important role in the occurrence and development of ovarian cancer, and is closely related to chemoresistance in ovarian cancer. Therefore, the receptors and kinases in this pathway may be potential targets of anticancer drugs for ovarian cancer. With the deepening of the research on this pathway and the discovery and invention of inhibitors, a new oncology therapeutic drug is developed for this signal transduction pathway , Targeted gene therapy, and looking for ways to reduce chemoresistance are undoubtedly of great importance for the treatment of ovarian cancer.